TL;DR
This study reveals that the two isoenzymes of Adenosine Deaminase, ADA1 and ADA2, play distinct and often opposing roles in various cancers. While ADA1 is generally associated with a poorer prognosis, ADA2 appears to be a protective factor, potentially by modulating the tumor immune microenvironment.
What Problem Does This Paper Address?
Adenosine deaminase (ADA) is an enzyme crucial for immune response, existing as two isoenzymes: ADA1 and ADA2. While ADA1 deficiency leads to severe combined immunodeficiency, ADA2 deficiency is linked to vascular and inflammatory issues. Both enzymes deaminate adenosine, a key immunosuppressive signal in the tumor microenvironment (TME). Despite the known roles of adenosine in cancer, the specific contributions of ADA1 and ADA2 to different cancer types and their impact on patient prognosis and immune infiltration remained unclear. This paper aims to dissect these distinct roles in a pan-cancer analysis.
Methods
The researchers employed a multi-pronged approach to investigate ADA1 and ADA2:
- Expression Profiling: They utilized the Human Protein Atlas (HPA) and Gene Expression Profiling Interactive Analysis (GEPIA2) databases to analyze mRNA expression levels of ADA1 and ADA2 in both normal and tumor tissues across various cancers.
- Enzyme Activity Assays: Serum samples from cancer patients were analyzed to measure the activity of ADA1 and ADA2.
- Prognostic Value Analysis: The Kaplan-Meier (KM) plotter was used to assess the association between ADA1/ADA2 expression levels and patient overall survival (OS).
- Immune Infiltration Analysis: The Tumor Immune Estimation Resource 2.0 (TIMER2.0) was employed to explore the correlation between ADA1/ADA2 expression and the infiltration of various immune cells, as well as immune checkpoints.
- Mutation Profiling: The cBioPortal database was used to investigate the mutation and alteration landscapes of ADA1 and ADA2 across different cancers.
- Gene Enrichment Analysis: LinkedOmics was used to identify genes correlated with ADA1 and ADA2 expression, followed by functional enrichment analysis using DAVID Bioinformatics Resources to understand the biological pathways involved.
Datasets
The study utilized publicly available datasets:
- Human Protein Atlas (HPA): For normal tissue expression profiles.
- Gene Expression Profiling Interactive Analysis (GEPIA2): Leveraging The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases for tumor vs. normal tissue expression analysis.
- Kaplan-Meier (KM) plotter: For survival analysis across multiple cancer types.
- Tumor Immune Estimation Resource 2.0 (TIMER2.0): For immune cell infiltration and immune checkpoint correlation analysis.
- cBioPortal for cancer genomics: For mutation and alteration frequency analysis.
- LinkedOmics: For identifying co-expressed genes.
- DAVID Bioinformatics Resources: For functional enrichment analysis.
- Clinical Samples: Serum samples from cancer patients were collected and analyzed for enzyme activity.
Key Insights and Ideas
- Opposing Prognostic Roles: The most striking finding is the diametrically opposed prognostic impact of ADA1 and ADA2. This suggests that simply looking at "adenosine deaminase activity" might mask crucial, distinct roles of its isoenzymes.
- Immune Microenvironment Modulation: The differential correlations of ADA1 and ADA2 with immune cells and checkpoints provide a potential mechanistic explanation for their opposing prognostic values. ADA2's strong positive correlation with beneficial immune cells (like CD8+ T cells) and negative correlation with immunosuppressive cells (like MDSCs) points to its role in fostering an anti-tumor immune response.
- Tissue-Specific Functions: The unique behavior of ADA1 in thymoma (THYM), where it's associated with better survival, highlights that the role of these enzymes can be context-dependent, possibly due to tissue-specific functions or interactions (e.g., ADA1's known role in thymus development).
- Extracellular vs. Intracellular Action: The observation that serum ADA2 levels are often elevated in cancers, while ADA1 levels are more variable, aligns with ADA2 being a secreted protein and ADA1 being primarily intracellular. This difference in localization likely influences their accessibility and impact within the TME.
Key Results
- Expression: ADA1 expression was significantly increased in several tumor types (e.g., cholangiocarcinoma, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma), while ADA2 was elevated in others (e.g., esophageal carcinoma, glioblastoma multiforme, skin cutaneous melanoma).
- Prognosis: High ADA1 expression was linked to poor survival in many cancers (e.g., ESCC, HNSC, KIRC), with the exception of thymoma. Conversely, high ADA2 expression was associated with favorable prognosis in a broad range of cancers (e.g., BRCA, CESC, HNSC, KIRC).
- Immune Infiltration: ADA1 showed moderate positive correlations with various immune cells, while ADA2 exhibited stronger positive correlations with B cells, CD8 T cells, monocytes/macrophages, and dendritic cells, and a strong negative correlation with myeloid-derived suppressor cells (MDSCs).
- Immune Checkpoints: Both ADA1 and ADA2 showed correlations with immune checkpoints, with ADA2 exhibiting a broader correlation profile.
- Mutations: The alteration frequency of ADA1 and ADA2 was generally low across most cancers.
- Serum Activity: Serum ADA2 activity was increased in most cancers, whereas serum ADA1 activity showed no significant changes in many cases.
Limitations and Future Work
- Correlation vs. Causation: The study primarily identifies correlations. While strong, these associations do not definitively prove causation. Further experimental studies are needed to establish the direct causal roles of ADA1 and ADA2 in cancer development and progression.
- Mechanistic Validation: The proposed mechanisms, particularly how ADA2's interaction with immune cells and its negative correlation with MDSCs contribute to favorable prognosis, require experimental validation.
- Therapeutic Potential: The study suggests that ADA2 might act as a protective factor, and its serum levels are easily measurable. This opens avenues for exploring ADA2 agonists or therapies targeting the adenosine pathway as potential cancer treatments, but this needs further investigation.
- ADA1 Inhibitor Studies: The paper suggests investigating the effects of ADA1 inhibitors, like EHNA, on tumor growth and metastasis, which could provide further insights into ADA1's role.
- Serum ADA2 Prognostic Value: While serum ADA2 activity was found to be elevated in many cancers, its prognostic value in serum has not yet been revealed, presenting an opportunity for future clinical application studies.
Summary updated